Boehringer Ingelheim is the second largest animal health business in the world, with more than 45 per cent of global revenue coming from the livestock side. The business is driven by innovative vaccines such as Bovela BVD vaccine and the Bovalto BRD vaccine range as well as parasiticides such as Eprinex, and therapeutics such as Metacam for Cattle.
We take responsibility seriously by bringing innovative health solutions to our customers. We focus our solutions on innovations that prevent disease in livestock. In doing so, we help livestock producers produce more high quality food using less natural resources.
We also strive to address some of the most pressing challenges facing our livestock customers, such as the need to cost-effectively produce more protein to feed the world's growing population. By 2050, the global population will reach 9.7 billion people, with a significant increase in the middle class, and substantial growth in emerging markets like Africa and Asia. As a result, the demand for animal protein is expected to increase by 70 per cent.
In response to a growing public health concern over antibiotic resistance and the need for food safety, we strive to develop solutions that prevent or reduce the need for antibiotics while at the same time improving the quality and safety of our food.
Last but not least, we help our customers tackle these challenges with preventive care solutions. Furthermore, we are increasing our focus on non-traditional animal health offerings, such as point-of-care diagnostic technologies, live therapeutics, and digital solutions.
For more information visit www.boehringer-ingelheim.com/animal-health/overview and www.calfmatters.com.< Back to Sponsors